

Programme

Thursday September 4, 2025

14:15 **Registration**

15:00 **Welcome and Opening Ceremony**

15:15 **Harnessing TRIM21 Mediated Protein Degradation, Selectively Degrading Pathological Protein Aggregates in the CNS (KL01)**

Dr Andrea TESTA
(TRIMTECH THERAPEUTICS, Cambridge, United Kingdom)

YMCS Competition Presentations - Session I

15:45 **Development of an Inhibitor of the Mutagenic Sos Response that Suppresses the Evolution of Quinolone Antibiotic Resistance (NH01)**

Mr Jacob BRADBURY (UNIVERSITY OF OXFORD, Oxford, United Kingdom)
(SOPLVIAS AG (WAS FUJIFILM))

15:50 **Chemoproteomic Interrogation of a Phenotypic Hit in Neuroblastoma to Guide Chemical Probe Development (NH02)**

Mr Aitor CARNEIRO
(THE UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

15:55 **A Tunable and Versatile Chemogenetic Near Infrared Fluorescent Reporter (NH03)**

Dr Lina EL HAJJI
(SORBONNE UNIVERSITÉ , Paris, France)

16:00 **Turning Down the Heat: Innovative Hsp90 Inhibition Strategies for Cancer Without Heat Shock Response Activation (OC01)**

Dr Jaka DERNOVSEK
(FACULTY OF PHARMACY, UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

16:15 **Flash poster presentations (0-10)**

16:45 **Coffee Break & Exhibition**

YMCS Competition Presentations - Session II

17:15 **Clarithomycin Bites the Heme: Mechanism-Based Destruction of Cyp3a4 Heme by a Clinical Macrolide (NH04)**

Ms Matea GADZA
(PHARMACEUTICAL RESEARCH INSTITUTE, Mostar, Bosnia and Herzegovina)

17:20 **Synthesis of Helical Peptides via One-Pot S-Alkylation/Reductive Amination (NH05)**

Mr François PIERRARD
(UCLOUVAIN, Brussels, Belgium)

17:25 **Unveiling the Antiglioblastoma Potential of Harmine-Based Hybrid Molecules (NH06)**

Dr Goran POJE
(FACULTY OF PHARMACY AND BIOCHEMISTRY, Zagreb, Croatia)

EFMC-YMCS 2025

Programme

- 17:30

YMCS Poster Presentation Session 1
- 18:45

EFMC-YSN Networking Event
- 19:45

End of the day

Programme

Friday September 5, 2025

08:00 EFMC-YSN Career Panel Discussion

YMCS Competition Presentations - Session III

09:00 HBV RNase H Targeting: A Promising Frontier in Hepatitis B Therapy (NH07)

Mrs Georgia Myrto PRIFTI
(NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, Athens, Greece)

09:05 Can Good Be Better? Derivatization of the Nobel Prize-Honored Drug – Ivermectin (NH08)

Mr Michal SULIK
(ADAM MICKIEWICZ UNIVERSITY IN POZNAN, Poznan, Poland)

09:10 Genome-Wide Signatures of Attack – How DNA Lesions Reveal the Mechanisms of Cancer Drugs Trabectedin and Irofulven (NH09)

Dr Vakil TAKHAVEEV
(ETH ZÜRICH, Zürich, Switzerland)

09:15 Enhancing the DMTA Cycle via Direct-to-Biology (D2B) and Parallel Medicinal Chemistry (PMC) at Merck KGaA (OC03)

Dr Alessia GAMBARDELLA (MERCK HEALTHCARE KGAA, Darmstadt, Germany)
Dr Paolo PIACENTINI (MERCK HEALTHCARE KGAA, Darmstadt, Germany)
(SOPLVIAS AG (WAS FUJIFILM))

09:30 Flash poster presentations (11-20)

10:00 Coffee Break and Exhibition

YMCS Competition Presentations - Session IV

10:30 Selective Nanomolar Inhibitors of Carbonic Anhydrases IX and XII: Coumarin Aminophosphonates as Potential Anticancer Agents (NH10)

Dr Manuela VORACOVA
(UNIVERSITY OF HELSINKI, Helsinki, Finland)

10:35 Design and Synthesis of PGE1-Photocages for the Investigation of Sperm-Specific Catsper Channels and their Role in Male Fertility (NH11)

Dr Wenxin Felix ZHU
(MÜNSTER UNIVERSITY, Münster, Germany)

10:40 FAPI Conjugates as Multifunctional Radiopharmaceuticals (NH12)

Ms Anna FRIEDEL
(FAU ERLANGEN-NÜRNBERG, UNIKLINIKUM ERLANGEN, Erlangen, Germany)

10:45 Chemical Cell Engineering Using Artificial Receptors for Targeted Protein Degradation and Drug Delivery

Dr Ane SOGAARD
(AARHUS UNIVERSITET, Aarhus, Denmark)

10:50 NH14 - To be announced

Programme

- 10:55** **NH15 - To be announced**
- 11:00** **Investigating the Functionality and Substrate Scope of β -Lactamases to Explore their Potential in Biocatalytic Drug Production (OC04)**
Ms Christine Marie ARNDT
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
- 11:15** **Synthesis and Evaluation of Bis-Carbapenem Narrow Spectrum Antibiotics to Combat the Emergence of Bacterial Resistance (OC05)**
Ms Katie BURKE
(UNIVERSITY PARIS CITÉ, Paris, France)
- 11:30** **Novel FLT3 Inhibitors Targeting FLT3-ITD Mutations in Acute Myeloid Leukemia (OC06)**
Dr Lukas GORECKI
(UNIVERSITY HOSPITAL HRADEC KRÁLOVÉ, BIOMEDICAL RESEARCH CENTER, Hradec Králové, Czech Republic)
- 11:45** **Novel Chemical Scaffolds to Expand the Toolbox of Hydrophobic Tags for Targeted Protein Degradation (OC07)**
Ms Celia ESCRICHE
(UNIVERSITY OF BARCELONA, Barcelona, Spain)
- 12:00** **Lunch and Exhibition**
- 13:00** **YMCS poster presentation session 2**
- YMCS Competition Presentations - Session V**
- 14:15** **Targeting Multidrug Resistance in Lung Cancer with Ru(II) Organometallic Compounds (OC08)**
Dr Ricardo TEIXEIRA
(CQE_IST, Lisboa, Portugal)
- 14:30** **Pt(IV) - Sunitinib Dual Action Pro-Drugs Display Enhanced Activity Against a Multitude of Cancer Types (OC09)**
Dr Darren Fergal BEIRNE
(MAYNOOTH, Navan, Ireland)
- 14:45** **YSN PhD Prize Lecture**
Dr Rebecca STEVENS
(BICYCLE THERAPEUTICS, Cambridge, United Kingdom)
- 15:00** **Coffee & Voting break**
- 15:30** **Elucidating and Exploiting Novel Microbial Pathways for Antibiotic Biosynthesis (KL02)**
Dr Joleen MASSCHELEIN
(KU LEUVEN, Leuven, Belgium)
- 16:00** **Closing and award ceremony**
- 16:15** **End of the Symposium**

Programme

Codes:
KL: Keynote Lecture
NH: National Highlight
OC: Oral Communication